UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 22, 2015
GlobeImmune, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-35642 | | 84-1353925 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
1450 Infinite Drive Louisville, CO | | 80027 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (303) 625-2700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 — Other Events
Other Events
On April 22, 2015, GlobeImmune, Inc., a Delaware corporation, announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute (NCI). Christopher Heery, M.D., Head of the Clinical Trials Group at the NCI Laboratory of Tumor Immunology and Biology, is the principal investigator for the study. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press Release titled “GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute” dated April 22, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | GlobeImmune, Inc. |
| | | |
| Dated: April 22, 2015 | | | | By: | | /s/ Timothy C. Rodell |
| | | | | | | | Timothy C. Rodell Chief Executive Officer and President |
INDEX TO EXHIBITS
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press Release titled “GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute” dated April 22, 2015. |
